William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company’s cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data.
https://thefly.com/landingPageNews.php?id=2884099
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.